Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 2548 results for methods

  1. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  2. Colli-Pee for first void urine collection (MIB273)

    NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .

  3. Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early-value assessment

    In development Reference number: GID-HTE10057 Expected publication date:  22 January 2026

  4. Blogs

    assessment Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real...

  5. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  6. StoneChecker for kidney stone evaluation (MIB171)

    NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .

  7. Endoscopic radical inguinal lymphadenectomy (IPG398)

    Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.

  8. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)

    Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.

  9. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  10. About our guidance

    Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

  11. Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)

    Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

  12. Transperineal template biopsy and mapping of the prostate (IPG364)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  13. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  14. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

  15. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

    Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.